165 citations,
September 2003 in “Toxicology and applied pharmacology” Blocking COX, especially COX-2, in the skin can reduce inflammation and pain and may help prevent skin cancer.
46 citations,
February 2012 in “Oncology Reports” Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.
25 citations,
May 2018 in “Clinical & Translational Oncology” New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.
22 citations,
October 2001 in “Biochemical Pharmacology” GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.
19 citations,
February 2010 in “Journal of Chemical & Engineering Data” Flutamide, dutasteride, and finasteride dissolve differently in supercritical carbon dioxide, with dutasteride dissolving the least.
11 citations,
January 1995 in “Biomedicine & pharmacotherapy” TURP is the best treatment for BPH, but some patients prefer medications like alpha-blockers and finasteride.
1 citations,
January 2024 in “Journal of molecular structure” The new finasteride delivery system using chitosan-based nanoniosomes shows promise for prostate cancer prevention.
24 citations,
July 1983 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Cyproterone acetate is used to treat conditions like prostate cancer, early puberty, excessive sexual drive, and female androgenization by blocking male sex hormones.
6 citations,
November 1998 in “The Journal of Clinical Pharmacology” Finasteride interacts with terazosin, but not doxazosin; caution needed.
3 citations,
January 2022 in “Pharmaceutics” Nanostructured delivery systems could potentially improve hair loss treatment by targeting drugs to hair follicles, reducing side effects and dosage, but the best size, charge, and materials for these systems need further investigation.
1 citations,
August 2022 in “Biomedicines” Dutasteride, usually used for prostate issues and hair loss, could potentially treat Amyotrophic Lateral Sclerosis (ALS) due to its neuroprotective, antioxidant, and anti-inflammatory properties, but more testing is needed.
December 2023 in “Alzheimer's & Dementia” Long-term use of a drug for hair loss and prostate issues can cause metabolic problems and depression-like behavior in young male rats.
June 2023 in “Pharmaceuticals” Men and women respond differently to drugs for COVID-19, high cholesterol, and diabetes, which suggests a need for personalized treatments.
129 citations,
January 1977 in “Hormone and metabolic research” Cyproterone Acetate effectively treats androgen-related conditions and is used in prostate cancer therapy and hormone therapy for transgender women.
44 citations,
July 2012 in “Endocrine Practice” We need to learn more about 5α-reductases and neuroactive steroids to safely make drugs targeting these enzymes.
39 citations,
April 2007 in “Therapeutic Drug Monitoring” Finasteride affects urinary steroid profiles and can potentially hide steroid abuse in sports drug testing.
5 citations,
December 2018 in “The Journal of clinical psychiatry/The journal of clinical psychiatry” Tamsulosin may slightly increase dementia risk compared to other treatments for enlarged prostate.
1 citations,
January 2024 in “Curēus” Clinicians should use social and prescription data to track trends in performance-enhancing drug use.
May 2023 in “Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy” A new green method accurately measures finasteride and tadalafil in drugs and plasma.
March 2021 in “Clin-Alert” The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.
728 citations,
August 1996 in “The New England Journal of Medicine” Terazosin and finasteride effectively treat BPH, but combining them adds no extra benefit.
195 citations,
February 2007 in “The Journal of Clinical Endocrinology and Metabolism” Dutasteride and finasteride may reduce sperm count and volume but don't affect movement or shape; effects are reversible after stopping.
59 citations,
September 2003 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Epitestosterone may counteract testosterone's effects and has roles in body processes like prostate growth and hair distribution.
52 citations,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
28 citations,
August 2003 in “Nature” Cosmeceuticals may have potential but their effectiveness and market success are still uncertain.
26 citations,
June 2005 in “Journal of Molecular Endocrinology” Dutasteride is more efficient than finasteride, but individual results vary.
26 citations,
February 2002 in “Urologic clinics of North America” The document concludes that it's important to understand the placebo effect when evaluating the effectiveness of treatments in medical trials.
12 citations,
December 2013 in “The Journal of Urology” Men's age, urinary symptoms, and heart health risks create different types of erectile dysfunction.
9 citations,
February 2018 in “Journal of Pharmaceutical and Biomedical Analysis” Quick, selective detection of tadalafil and finasteride in human plasma developed.
8 citations,
June 2017 in “Steroids” New chemical compounds were made that effectively block an enzyme linked to prostate growth.